Scorpion

Scorpion Therapeutics is a precision clinical stage oncology company developing small molecule drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy. Scorpion was acquired by Eli Lilly in a transaction with an overall value of up to $2.5b. The acquisition relates to Scorpion’s lead program, STX-478, a PI3Kα kinase inhibitor currently being evaluated for treatment of breast cancer and other advanced solid tumors.